M echanical ventilation (MV)
is used clinically to maintain adequate alveolar ventilation for patients unable to do so. Although MV is a lifesaving intervention in patients suffering from respiratory failure, prolonged MV results in a rapid development of diaphragm weakness, due to both diaphragmatic atrophy and contractile dysfunction (1) (2) (3) . MV-induced diaphragmatic weakness is potentially important because respiratory muscle weakness is predicted to contribute to the difficulties in weaning patients from the ventilator (4) . At present, the signaling pathways responsible for this rapid onset of diaphragmatic weakness remain unclear. Therefore, insight into these pathways is essential to develop a therapeutic strategy for preventing MV-induced diaphragmatic weakness.
During prolonged MV, several key proteolytic enzymes are activated in diaphragm muscle, including calpain, caspase-3, and the proteasome (2, 5) . Although all three proteases contribute to proteolysis, it appears that calpain and caspase-3 play a crucial role in MV-induced diaphragmatic weakness. Indeed, pharmacological inhibition of calpain can protect the diaphragm from MV-induced proteolysis, atrophy, and contractile dysfunction (6) . Furthermore, inhibition of caspase-3 can also protect against MV-induced diaphragmatic atrophy (5) . Together, these findings raise an intriguing question, why does selective inhibition of either protease protect the diaphragm from MV-induced dysfunction? A potential answer to this question is that a regulatory cross-talk exists between calpain and caspase-3 in the diaphragm during prolonged MV, whereby they can activate each other. It is currently unknown if a regulatory cross-talk exists in skeletal muscle, but it has been reported that in neurons during cerebral ischemia reperfusion injury, calpain can activate caspase-3 and conversely, caspase-3 can regulate calpain activation (7) . Several potential mechanisms may explain this regulatory interaction in neurons. For example, it is feasible that active caspase-3 can promote calpain activation by degrading the endogenous calpain inhibitor, calpastatin (8) . Furthermore, calpain can facilitate caspase-3 activation via several potential upstream pathways Objective: Diaphragmatic weakness, due to both atrophy and contractile dysfunction, is a well-documented response following prolonged mechanical ventilation. evidence indicates that activation of the proteases calpain and caspase-3 is essential for mechanical ventilation-induced diaphragmatic weakness to occur. We tested the hypothesis that a regulatory cross-talk exists between calpain and caspase-3 in the diaphragm during prolonged mechanical ventilation. To test this prediction, we determined whether selective pharmacological inhibition of calpain would prevent activation of caspase-3 and conversely whether selective inhibition of caspase-3 would abate calpain activation.
Design: Animal study. Setting: University research Laboratory. Subjects: Female Sprague-Dawley rats.
Interventions: Animals were randomly divided into control or one of three 12-hr mechanical ventilation groups that were treated with/without a selective pharmacological protease inhibitor: 1) control, 2) mechanical ventilation, 3) mechanical ventilation with a selective caspase-3 inhibitor, and 4) mechanical ventilation with a selective calpain inhibitor.
Measurements and Main Results: Compared to control, mechanical ventilation resulted in calpain and caspase-3 activation in the diaphragm accompanied by atrophy of type I, type IIa, and type IIx/ IIb fibers. Independent inhibition of either calpain or caspase-3 prevented this mechanical ventilation-induced atrophy. Pharmacological inhibition of calpain prevented mechanical ventilation-induced activation of diaphragmatic caspase-3 and inhibition of caspase-3 prevented activation of diaphragmatic calpain. Furthermore, calpain inhibition also prevented the activation of caspase-9 and caspase-12, along with the cleavage of Bid to tBid, all upstream signals for caspase-3 activation. Lastly, caspase-3 inhibition prevented the mechanical ventilation-induced degradation of the endogenous calpain inhibitor, calpastatin.
Conclusions: Collectively, these results indicate that mechanical ventilation-induced diaphragmatic atrophy is dependent on the activation of both calpain and caspase-3. Importantly, these findings provide the first experimental evidence in diaphragm muscle that calpain inhibition prevents the activation of caspase-3 and vice versa and caspase-3 inhibition prevents the activation of calpain. These findings support our hypothesis that a regulatory calpain/caspase-3 cross-talk exists whereby calpain can promote caspase-3 activation and active caspase-3 can enhance calpain activity in diaphragm muscle during prolonged mechanical ventilation. ( (e.g., activation of Bid and/or Bax) (9) (10) (11) . Based on both published work and our preliminary experiments, we formulated the hypothesis that during prolonged MV, a regulatory cross-talk occurs in the diaphragm between the calpain and caspase-3 proteolytic systems, whereby active calpain can activate caspase-3 and vice versa. Our findings support this hypothesis and reveal that during MV, inhibition of diaphragmatic calpain activity prevented activation of caspase-3 and inhibition of caspase-3 prevented activation of calpain. These data provide the first evidence that during prolonged MV, calpain and caspase-3 participate in regulatory cross-talk in diaphragm muscle.
METHODS
Experimental Design. Young adult female Sprague-Dawley rats were assigned to one of four experimental groups (n = 8 per group): 1) control, 2) 12 hrs of MV, 3) 12 hrs of MV with a specific caspase-3 inhibitor, and 4) 12 hrs of MV with a specific calpain inhibitor. The Institutional Animal Care and Use Committee of the University of Florida approved these experiments.
Control Animals and MV. Control animals were acutely anesthetized with sodium pentobarbital (60 mg/kg body weight intraperitoneally). After reaching a surgical plane of anesthesia, the diaphragms were quickly removed and the costal diaphragm was divided into several segments. A strip of the medial costal diaphragm was immediately used for in vitro contractile measurements, a separate section was stored for histological measurements, and the remaining portions of the costal diaphragm were rapidly frozen in liquid nitrogen and stored at −80°C for subsequent biochemical analyses.
MV animals were tracheostomized and mechanically ventilated with a pressurecontrolled ventilator (Servo Ventilator 300; Siemens AG, Munich, Germany) for 12 hrs, as previously reported (12) .
Calpain Inhibition. To prevent MV-induced diaphragmatic calpain activation, we administered 3 mg/kg body weight of SJA-6017 dissolved in 88% propylene, 10% ethyl alcohol, 2% benzyl alcohol, and given intravenously as a bolus at the beginning of MV (Calpain Inhibitor VI, N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal; EMD Chemicals, Gibbstown, NJ).
Caspase-3 Inhibition. To prevent MV-induced diaphragmatic caspase-3 activation, we administered 3 mg/kg body weight of AC-DEVD-CHO (Asp-Glu-Val-Asp-CHO) dissolved in 0.9% sterile saline and given intravenously as a bolus at the beginning of MV (AC-DEVD-CHO; Enzo Life Sciences, Farmingdale, NY).
Western Blot Analysis. Diaphragmatic protein extracts were assayed, as previously described (12) . Membranes were probed for 4-hydroxyl-nonenal-conjugated (Abcam, Cambridge, MA), (active) calpain-1, cleaved caspase-3, cleaved caspase-9, cleaved caspase-8 (Cell Signaling Technology, Danvers, MA), Bid/ tBid (Imgenex, San Diego, CA), total calpain, calpastatin, -II spectrin, and cleaved caspase-12 (Santa Cruz Biotechnology, Santa Cruz, CA). To control for protein loading and transfer differences, membranes were stained with Ponceau S (see Supplemental Digital Content 1, http://links.lww.com/CCM/A407). Ponceau S-stained membranes were scanned and the lanes were quantified (440CF Imaging System; Kodak, New Haven, CT) to normalize western blots to protein loading.
Measurement of In Vitro Diaphragmatic Contractile Properties. Upon sacrifice, a muscle strip, including the tendinous attachments at the central tendon and rib cage, was dissected from the mid-costal region. The strip was suspended vertically with one end connected to an isometric force transducer (model FT-03; Grass Instruments, Quincy, MA) within a jacketed tissue bath and diaphragm skeletal muscle contractile properties were measured as previously reported (3).
Myofiber Cross-Sectional Area. Sections from frozen diaphragm samples were cut at 10 μm using a cryotome (Shandon, Pittsburgh, PA) and immunohistochemically stained as described previously (5) . Cross-sectional area was determined using Scion Software (National Institutes of Health, Bethesda, MD).
Statistical Analysis. Comparisons between groups for each dependent variable were made by a one-way analysis of variance and, when appropriate, Tukey's honestly significant difference test was performed post hoc. Significance was established at p < .05. Data are presented as means ± SEM.
RESULTS
Physiological Responses to Prolonged MV. To ensure that our MV protocol was successful in maintaining homeostasis, we measured arterial blood pressures, arterial PCO 2 , arterial PO 2 , and arterial pH in all animals at the beginning of the experiments and at various time intervals during MV. Our results confirm that arterial blood pressure (mean 102 ± 4 mm Hg), arterial PO 2 (mean 87 ± 5 torr [11.6 ± 0.6 kPa]), arterial PCO 2 (mean 39 ± 2 torr [5.2 ± 0.3 kPa]), and pH (range 7.3-7.5) were maintained during MV. Furthermore, during the course of MV, no significant (p < .05) changes occurred in the body weights of our animals.
Pharmacological Inhibitors Selectively Inhibited Their Respective Proteases and Did Not Exhibit Antioxidant Properties.
We evaluated the selectivity of our calpain and caspase-3 inhibitors with independent in vitro activity assays using the predicted peak in vivo concentrations of each inhibitor. Our results reveal that calpain proteolytic activity in vitro was not diminished when incubated in the presence of the caspase-3 inhibitor. Furthermore, caspase-3 proteolytic activity was not reduced when incubated in the presence of the calpain inhibitor. Finally, our results also reveal that caspase-9 enzymatic activity was not blunted when incubated in the presence of the calpain inhibitor (see Supplemental Digital Content 1, http:// links.lww.com/CCM/A407). Note, however, that caspase-9 activity was diminished in the presence of the caspase-3 inhibitor. Due to the lack of a commercially available purified caspase-12 enzyme, we were not able to determine the effects of the calpain or caspase-3 inhibitor on caspase-12 activity. Collectively, these results indicate that our primary experimental findings are not influenced by off-target effects of our pharmacological inhibitors.
Furthermore, to determine whether our protease inhibitors exhibited antioxidant properties and protected against MV-induced oxidative damage in the diaphragm, we measured a reliable biomarker of oxidative damage (i.e., 4-hydroxyl-nonenal-conjugated conjugated proteins). Compared to control, diaphragmatic levels of 4-hydroxyl-nonenal-conjugated were higher in all of the MV groups ( Fig. 1) . Importantly, no differences existed in diaphragmatic levels of 4-hydroxyl-nonenal-conjugated between the MV groups, indicating that the proteolytic inhibitors did not exhibit antioxidant properties.
Inhibition of Calpain and Caspase-3 Prevents MV-Induced Contractile Dysfunction and Atrophy. To assess the impact of 12 hrs of MV on diaphragm contractile dysfunction, we measured diaphragm contractile performance in vitro using strips of diaphragm muscle. Similar to previous studies (3, 6, (12) (13) (14) (15) , 12 hrs of MV resulted in a significant decrease in diaphragmatic force production at both submaximal and maximal stimulation frequencies (Fig. 2) . Selective inhibition of calpain and caspase-3 rescued the diaphragm from MV-induced contractile dysfunction at all stimulation frequencies above 15 Hz. Importantly, this is the first report indicating that inhibition of caspase-3 can protect the diaphragm from MV-induced contractile dysfunction.
Previous work shows that both calpain and caspase-3 activation are sufficient to result in MV-induced diaphragmatic atrophy (5, 6) . Indeed, compared to control animals, MV induced a ~27% decrease in fiber cross-sectional area in type I fibers, a ~18% decrease in type IIa fibers, and a ~18% decrease in type IIx/IIb fibers. However, both calpain and caspase-3 inhibition prevented the MV-induced decreases in cross-sectional area of type I and IIa fibers (Fig. 3) . Additionally, calpain inhibition prevented the MV-induced atrophy in type IIx/IIb fibers.
Calpain and Caspase-3 Activity Increased During 12 Hrs of MV. Consistent with previous reports (5, 12) , 12 hrs of MV increased both calpain-1 and caspase-3 activity in the diaphragm ( Fig. 4A and C) . Furthermore, MV increased diaphragmatic levels of the calpain and caspase-3-specific -II spectrin degradation products; these independent degradation products are excellent biomarkers of in vivo protease activity ( Fig. 4B and D) .
Calpain Inhibitor Prevented Calpain Activity and the Caspase-3 Inhibitor Prevented Caspase-3 Activity. To evaluate the effectiveness of our protease inhibitors, we measured markers of their respective protease activities after 12 hrs of MV. As expected, pharmacological inhibition of calpain activity prevented MV-induced increases in active calpain-1 and the accumulation of the calpainspecific -II spectrin degradation product in the diaphragm (Fig. 4A and B) . Similarly, pharmacological inhibition of caspase-3 prevented the MV-induced increases in active caspase-3 and the caspase-3-specific -II spectrin degradation product within the diaphragm ( Fig. 4C and D) .
Calpain Inhibition Prevented Caspase-3 Activation and Conversely, Caspase-3 Inhibition Prevented Calpain Activation. Importantly, when animals were treated with the calpain inhibitor, there was an attenuation in the MVinduced increase in active caspase-3 ( Fig. 4C ) and the caspase-3-specific -II spectrin degradation product in the diaphragm (Fig. 4D) . Similarly, 12 hrs of MV with the caspase-3 inhibitor reduced the MV-induced increases in active calpain-1 (Fig. 4A ) and the calpain-1-specific -II spectrin cleavage product in diaphragm fibers (Fig. 4B ). Collectively, these results indicate that inhibition of calpain prevents the activation of caspase-3 and vice versa. These findings are important and clearly support the hypothesis that regulatory cross-talk exists between calpain and caspase-3 in the diaphragm during prolonged MV.
Calpain Inhibition Alters Upstream Caspase-3 Signaling. To investigate the basis for the regulatory cross-talk between calpain and caspase-3, we performed additional measurements to gain insight into how calpain can activate caspase-3. We measured the activities of both caspase-9 and -12, as these caspases are upstream activators of caspase-3 and both proteases can be activated either directly by calpain (e.g., caspase-12) or indirectly as a downstream by-product of calpain action (e.g., caspase-9) (16). Our results reveal that 12 hrs of MV result in activation of both caspase-9 and caspase-12 in the diaphragm. However, pharmacological inhibition of calpain prevented the MVinduced activation of both caspase-9 and caspase-12 in the diaphragm (Fig. 5, A and  B) . Furthermore, to determine whether the death receptor caspase-8 pathway contributed to MV-induced caspase-3 activation, we measured caspase-8 activity in the diaphragm. Our results revealed that caspase-8 is not activated in the diaphragm during prolonged MV (Fig. 5C ). These findings indicate that MV-induced caspase-3 activation in the diaphragm is regulated via an intrinsic pathway and not through an extracellular mechanism.
To determine whether calpain activates upstream proapoptotic factors that promote caspase-9 and subsequent caspase-3 activation in the diaphragm, we measured the calpain-mediated cleavage of Bid into truncated Bid (tBid). tBid is a pro-apoptotic molecule that translocates to the mitochondria and interacts with other pro-apoptotic molecules (e.g., Bak and Bax) to initiate mitochondrial release of cytochrome C, leading to caspase-3 activation. Compared to control, the diaphragmatic Bid/tBid ratio was significantly lower in diaphragms from mechanically ventilated animals ( Fig. 6C) , indicating increased proteolytic cleavage of Bid into tBid. Importantly, the inhibition of calpain prevented this decrease in the Bid/tBid ratio, demonstrating that calpain is required for the formation of tBid in the diaphragm during prolonged MV (Fig. 6C) .
Caspase-3 Inhibition Prevents Degradation of Calpastatin. To investigate the mechanism for caspase-3 to activate calpain, we measured diaphragmatic levels of total calpain and calpastatin. Calpastatin is an endogenous inhibitor of calpain activation and also a substrate of caspase-3 (8) . The ratio of total calpain to calpastatin is an indicator of calpain activity and when the calpain/calpastatin ratio increases, it reflects a degradation of calpastatin and a subsequent likely increase in calpain activity. Compared to control, prolonged MV resulted in a significant increase in the diaphragmatic calpain/calpastatin ratio (Fig. 7C ). However, inhibition of caspase-3 in the diaphragm during prolonged MV preserved the levels of calpastatin and the calpain/calpastatin ratio remained low, similar to control (Fig. 7C ). B, Levels of the 145 kDa -II-spectrin breakdown product (SBDP) in diaphragm muscle following 12 hrs of MV. Note that the SBDP 145 kDa is an -II-SBDP that is specific to calpain cleavage of intact -II-spectrin. C, The cleaved and active band of caspase-3 in diaphragm muscle at the completion of 12 hrs of MV. D, Levels of the 120 kDa -II-SBDP in diaphragm muscle following 12 hrs of MV. Note that the SBDP 120 kDa is an -II-spectrin breakdown product that is specific to caspase-3 cleavage of intact -II-spectrin. 
DISCUSSION

Overview of the Major Findings.
Collectively, these results indicate that MVinduced diaphragmatic atrophy is dependent on the activation of both calpain and caspase-3. Importantly, these experiments provide the first experimental evidence that a regulatory cross-talk exists between calpain and caspase-3 in diaphragm muscle during prolonged MV. A detailed discussion of these results follows.
Biochemical Basis of Calpain/ Caspase-3 Cross-Talk. The first evidence that a regulatory cross-talk exists between calpain and caspase-3 originated from in vitro experiments in nonmuscle cells (7, 9, (17) (18) (19) . Although calpain activity is regulated by several factors, it is clear that increased free calcium in the cytosol is essential for calpain activation. Calpain activity is also regulated by the endogenous calpain inhibitor calpastatin and a decrease in cellular levels of calpastatin is a requirement for full activation of calpain (20, 21) . Interestingly, calpastatin is a substrate for both calpain and caspase-3 (8) . Indeed, active caspase-3 has been shown to rapidly degrade calpastatin and promote calpain activation in cells (8) .
Evidence also suggests that calpain can increase caspase-3 activation through several signaling pathways. Specifically, active calpain can cleave procaspase-12 to generate active caspase-12 (16, 22) , which can then activate caspase-3 with or without caspase-9 as an intermediate (22, 23) . Alternatively, calpain can act on pro-apoptotic proteins such as Bid and Bax (9) (10) (11) . Once activated, these pro-apoptotic factors can form a pore in the mitochondrial outer membrane, promoting the release of cytochrome C from the mitochondria into the cytosol (9, 24, 25) . Following release from the mitochondria, cytochrome C can then bind to the cytosolic protein Apaf-1 to form the apoptosome, which activates caspase-3 via a caspase-9, mediated pathway (26, 27) . Therefore, a sound theoretical basis for a calpain/caspase-3 cross-talk exists and a regulatory interaction between these proteases has been reported in nonmuscle cells during neural ischemia-reperfusion (7, 9) , in vitro apoptosis (17, 18) and photoreceptor degeneration (19) .
Regulatory Cross-talk Between Calpain/Caspase-3 Exists in Diaphragm Muscle During MV. Our previous work and the current study clearly demonstrate that prolonged MV activates both calpain and caspase-3 in the diaphragm and that activation of these proteases plays a key role in MV-induced diaphragmatic atrophy and contractile dysfunction (5, 6) . Importantly, the present study provides the first evidence that a regulatory cross-talk exists between the calpain and caspase-3 proteolytic systems in diaphragm muscle dur-figure 6. Bid, tBid, and the Bid/tBid ratio in the diaphragm of the four experimental groups. A, Bid levels in the diaphragm at the completion of 12 hrs of mechanical ventilation (MV). Note that the 23-kDa band represents Bid. B, tBid levels in the diaphragm at the completion of 12 hrs of MV. Note that the 15-kDa band represents the cleaved form of Bid, tBid. C, Bid/tBid ratio in the diaphragm at the completion of 12 hrs of MV. The image above the histograms in this figure is a representative western blot of data from the four experimental groups. Values are means ± SEM. *Different (p < .05) from all other groups. Inhib, inhibitor. ing MV, whereby active calpain promotes caspase-3 activation and vice versa.
To investigate potential mechanisms responsible for the calpain-mediated activation of capase-3, we measured the activities of two upstream activators of caspase-3 (i.e., capase-9 and caspase-12) in the diaphragm. Our results reveal that during prolonged MV, the activities of both caspase-9 and caspase-12 are increased in the diaphragm. Furthermore, pharmacological inhibition of calpain prevented the MV-induced activation of both caspase-9 and -12 and also averted the activation of caspase-3. These observations support previous in vitro findings that calpain activation plays an important role in the activity of caspase-3, caspase-9, and caspase-12 (16) .
Our data also suggest that calpain can activate caspase-3, at least in part, by activating pro-apoptotic factors and activation of caspase-9 via a mitochondrialmediated pathway. Indeed, previous work using an in vivo model of cardiac ischemia reperfusion injury indicates that calpain can cleave Bid into the pro-apoptotic factor tBid (9) . In the current experiments, compared to control, the Bid/tBid ratio decreased in diaphragms from mechanically ventilated animals, indicating that prolonged MV initiates cleavage of Bid to form tBid. However, when MV animals were treated with a calpain inhibitor, Bid cleavage was prevented and diaphragm tBid levels remained similar to control.
Interestingly, treatment of animals with the caspase-3 inhibitor also protected against MV-induced tBid formation in the diaphragm. There are two possible explanations for this observation. First, because inhibition of caspase-3 also prevents calpain activation, it is feasible that this finding was due to the failure to activate calpain in the diaphragm. A second possibility is that, during prolonged MV, active caspase-3 can cleave Bid to form tBid. In this regard, evidence from in vitro experiments indicates that purified active caspase-3 can cleave recombinant Bid (28) . However, it remains unknown if active caspase-3 can cleave Bid in myofibers in vivo.
We also investigated the mechanism responsible for the finding that caspase-3 activation is a requirement for calpain activation in the diaphragm during MV. Based on previous work indicating that caspase-3 can degrade calpain's endogenous inhibitor calpastatin (8), we predicted that inhibition of caspase-3 would preserve diaphragmatic levels of calpastatin and therefore, retard the MV-induced action of calpain. Our findings support this postulate and reveal that when caspase-3 activity was inhibited in the diaphragm during MV, the calpain/calpastatin ratio remained at control levels and calpain was not activated. Collectively, these results are consistent with the concept that caspase-3 can regulate calpain activity, at least in part, via the degradation of calpastatin.
It is evident from our results that the loss of either calpain or caspase-3 activity is sufficient to prevent diaphragmatic atrophy and weakness. At the core of this observation is the finding that calpain can activate caspase-3 and vice versa. Clearly, either calpain or caspase-3 must be activated at some level to initiate the regulatory cross-talk between these proteases. Hence, this raises two important questions, which protease is activated first and how is it activated? During prolonged MV, an increased production of reactive oxygen species is a requirement for increased diaphragmatic proteolysis and atrophy (12, 13) . In experimental models of reactive oxygen species-mediated apoptosis in cell culture, it appears that calpain is activated first and in turn activates caspase-3 (17, 29, 30) . This is a plausible scenario in our experimental model, given that skeletal muscle inactivity results in both an increase in cellular reactive oxygen species production and elevated levels of cytosolic calcium which can ultimately lead to calpain activation (31, 32) . Nonetheless, our current data cannot resolve which protease (i.e., calpain or caspase-3) is activated first in the diaphragm during prolonged MV.
In contrast to the current results, Supinski et al (33) reported that while both calpain and caspase-3 contribute to sepsis-induced diaphragmatic muscle wasting, there was no direct evidence of a regulatory cross talk between these proteases. In sepsis-induced diaphragm wasting, the investigators propose that calpain and caspase-3 are activated in parallel and remain independently active, downstream of a common inflammatory signal (i.e., cytokines). The disparity between the current experiments and the work of Supinski et al (33) may be due to the differences between the two experimental models. In the sepsis model of muscle wasting, there is an inflammatory response which results in caspase-3 activation via the extrinsic apoptotic caspase-8 pathway (34) . Conversely, in healthy rats, prolonged MV is not associated with an increase in circulating cytokines (35) and our results show that caspase-8 is not activated in the diaphragm. Therefore, the divergent results between the current study and the work of Supinski et al could indicate that the signaling pathways regulating caspase-3 activation in skeletal muscle vary between different conditions of muscle wasting.
Critique of the Experimental Model. Because of the invasive nature of obtaining diaphragm muscle samples from humans, an animal model is required to perform mechanistic experiments to explore the signaling pathways that promote MV-induced diaphragmatic weakness. We selected the rat as the experimental animal in these experiments for several reasons. First, the anatomical features and function of the rat diaphragm are both similar to the human diaphragm (36, 37) . Second, the fiber type composition of the rat and human diaphragm are comparable (1, 38) . Finally, the time course of MV-induced atrophy in the rat and human diaphragm are also similar (1, 2) .
The protease inhibitors used in these experiments were chosen due to their ability to effectively inhibit calpain and caspase-3 in vivo and because of their high level of specificity. As discussed in the Methods and Results sections, to confirm that these inhibitors are highly selective in our experimental model, we performed in vitro experiments using the estimated peak in vivo concentrations of the protease inhibitors used in these experiments. Our results confirm that the calpain inhibitor (SJA-6017) does not inhibit caspase-3 activity and likewise, the caspase-3 inhibitor (AC-DEVD-CHO) does not inhibit calpain. Also, note that SJA-6017 does not inhibit caspase-9. Collectively, these findings confirm the high level of selectivity of our pharmacological probes and demonstrate that our results are not due to off-target pharmacological effects.
